AIMS: To determine whether topical ocular chloramphenicol increases the risk of aplastic anaemia and to estimate the magnitude of this risk, if any. METHODS: Population-based prospective case-control surveillance of aplastic anaemia in a community of 4.2 million inhabitants from 1980 to 1995 (67.2 million person-years) plus case-population estimate of the risk, based on sales figures of ocular chloramphenicol in the study area during the study period. RESULTS: One hundred and forty-five patients with aplastic anaemia and 1,226 controls were included in the analysis. Three cases (2.1%) and 5 controls (0.4%) had been exposed to ocular chloramphenicol during the relevant etiological period. The adjusted odds ratio was 3.77 (95% confidence interval, 0.84-16.90). Two cases had also been exposed to other known causes of aplastic anaemia. The incidence of aplastic anaemia among users of ocular chloramphenicol was 0.36 cases per million weeks of treatment. The incidence among non users was 0.04 cases per million weeks. CONCLUSIONS: An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses.
AIMS: To determine whether topical ocular chloramphenicol increases the risk of aplastic anaemia and to estimate the magnitude of this risk, if any. METHODS: Population-based prospective case-control surveillance of aplastic anaemia in a community of 4.2 million inhabitants from 1980 to 1995 (67.2 million person-years) plus case-population estimate of the risk, based on sales figures of ocular chloramphenicol in the study area during the study period. RESULTS: One hundred and forty-five patients with aplastic anaemia and 1,226 controls were included in the analysis. Three cases (2.1%) and 5 controls (0.4%) had been exposed to ocular chloramphenicol during the relevant etiological period. The adjusted odds ratio was 3.77 (95% confidence interval, 0.84-16.90). Two cases had also been exposed to other known causes of aplastic anaemia. The incidence of aplastic anaemia among users of ocular chloramphenicol was 0.36 cases per million weeks of treatment. The incidence among non users was 0.04 cases per million weeks. CONCLUSIONS: An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses.
Authors: Mathias Roth; Paul Goerke; Christoph Holtmann; Andreas Frings; Colin R MacKenzie; Gerd Geerling Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-06-10 Impact factor: 3.117
Authors: Clare F Heal; Petra G Buettner; Robert Cruickshank; David Graham; Sheldon Browning; Jayne Pendergast; Herwig Drobetz; Robert Gluer; Carl Lisec Journal: BMJ Date: 2009-01-15
Authors: Jarir At Thobari; Cahya Dewi Satria; Yohanes Ridora; Emma Watts; Amanda Handley; Samad Samad; Novilia S Bachtiar; Julie E Bines; Yati Soenarto; Jim P Buttery Journal: PLoS One Date: 2019-08-05 Impact factor: 3.240